Hims & Hers Health, Inc. Class A Common Stock (HIMS)
31.49
0.00 (0.00%)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care
The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery.

Shares of telehealth company Hims & Hers Health (NYSEHIMS) fell 8% in the afternoon session after the U.S. Food and Drug Administration raised concerns about unapproved GLP-1 drugs used for weight loss, including versions (compounded) prescribed by Hims & Hers. There had been growing market demand for weight loss drugs in recent months, and they've evolved to be a significant driver of sales growth for manufacturers and distributors. The FDA's concerns could indicate tighter regulatory scrutiny, which restricts the ability of suppliers like Hims & Hers to get the affected versions to consumers.
Via StockStory · March 18, 2025

Bank of America just delivered an incredibly back-handed compliment to Hims & Hers stock.
Via The Motley Fool · March 18, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 9.4%. This performance was disappointing since the S&P 500 held its ground.
Via StockStory · March 18, 2025

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.
Via MarketBeat · March 18, 2025

Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?
Via The Motley Fool · March 17, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Via StockStory · March 13, 2025

Here are four stocks to buy now that could offer investors upside in the short and long terms.
Via The Motley Fool · March 11, 2025

Via Benzinga · March 6, 2025

Shutting down an acquisition caught investor attention, but there's more to the story.
Via The Motley Fool · March 11, 2025

These three stocks tumbled by at least 20% last week, but they may not be down for long.
Via The Motley Fool · March 10, 2025

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.
Via MarketBeat · March 10, 2025

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue
Via MarketBeat · March 8, 2025

Via The Motley Fool · March 5, 2025

The news slammed Hims stock. Hims & Hers sells knockoff versions of semaglutide, the chemical backbone behind Wegovy.
Via Investor's Business Daily · March 5, 2025

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.
Via MarketBeat · March 5, 2025

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy.
Via Benzinga · March 5, 2025

These were the 20 tickers that Benzinga readers searched for the most during the month of February.
Via Benzinga · March 4, 2025

U.S. markets suffered a steep selloff Monday as President Donald Trump announced sweeping new tariffs, extending last week's losses and driving declines across all major sectors.
Via Benzinga · March 4, 2025